Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01DK129885 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institutes of Health (NIH) | NIH |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NIH |
Not provided
Not provided
Not provided
Not provided
This study is looking to understand the role of oxalate on kidney stone development and immunity. This study will enroll healthy participants and participants with calcium oxalate kidney stones (CaOx KS). Participants will be in this study for about 3 weeks, consume controlled diets, and provide blood and urine specimens.
The purpose of this longitudinal study is to examine the effects of dietary oxalate on nanocrystalluria and the immune system. Oxalate is a small molecule found in plants and plant-derived food. It has been shown that meals containing high amounts of oxalate can increase urinary oxalate excretion, which is a risk factor for calcium oxalate kidney stones (CaOx KS). Small increases in oxalate can stimulate urinary crystals to form which can elicit an immune response. This study consists of having healthy subjects and patients with CaOx KS consume both low and oxalate enriched diets to evaluate the effect of oxalate on urinary crystals and immune responses. Participants will receive a low or high oxalate diet for 4 days prior to having a wash-out period for 6 days. Participants will then crossover to the opposite oxalate diet for four more days.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Healthy Participants | Experimental | Healthy participants will randomly receive either high (250mg) or low (40mg) oxalate diet for for four days, a ten day "washout" period on a self-selected diet, and finally the opposite diet from the first for the last four days. |
|
| Calcium Oxalate Kidney Stone | Experimental | Calcium oxalate kidney stone participants will randomly receive either high (250mg) or low (40mg) oxalate diet for for four days, a ten day "washout" period on a self-selected diet, and finally the opposite diet from the first for the last four days. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Low Oxalate Diet | Dietary Supplement | Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Urinary Oxalate | Twenty-four hour urinary oxalate will be reported as mg/day. | Days 3-4 and 13-14 |
| Change in Nanocystalluria | Nanocrystalluria will be reported as particles/ml. | Days 3-4 and 13-14 |
| Monocyte Cellular Bioenergetics and Mitochondrial Function | Cellular bioenergetics and mitochondrial function will be reported as oxygen consumption rate (pmol/min/10,000 cells). | Day 1 |
| Monocyte Cellular Bioenergetics and Mitochondrial Function | Cellular bioenergetics and mitochondrial function will be reported as oxygen consumption rate (pmol/min/10,000 cells). | Day 4 |
| Monocyte Cellular Bioenergetics and Mitochondrial Function | Cellular bioenergetics and mitochondrial function will be reported as oxygen consumption rate (pmol/min/10,000 cells). | Day 11 |
| Monocyte Cellular Bioenergetics and Mitochondrial Function | Cellular bioenergetics and mitochondrial function will be reported as oxygen consumption rate (pmol/min/10,000 cells). | Day 14 |
| Monocyte Subtypes | Monocyte subtypes will be determined using flow cytometry (mean fluorescence intensity). | Day 1 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Tanecia Mitchell, PhD | Contact | (205) 996-2292 | taneciamitchell@uabmc.edu |
| Name | Affiliation | Role |
|---|---|---|
| Tanecia Mitchell, PhD | University of Alabama at Birmingham | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Alabama at Birmingham | Recruiting | Birmingham | Alabama | 35294 | United States |
Not provided
| ID | Term |
|---|---|
| D007669 | Kidney Calculi |
| ID | Term |
|---|---|
| D053040 | Nephrolithiasis |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| High Oxalate Diet | Dietary Supplement | Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them. |
|
| Monocyte Subtypes |
Monocyte subtypes will be determined using flow cytometry (mean fluorescence intensity). |
| Day 4 |
| Monocyte Subtypes | Monocyte subtypes will be determined using flow cytometry (mean fluorescence intensity). | Day 11 |
| Monocyte Subtypes | Monocyte subtypes will be determined using flow cytometry (mean fluorescence intensity). | Day 14 |
| Monocyte Transcriptomics | Monocyte transcriptomics will be reported as gene expression (mRNA levels) | Day 1 |
| Monocyte Transcriptomics | Monocyte transcriptomics will be reported as gene expression (mRNA levels) | Day 4 |
| Monocyte Transcriptomics | Monocyte transcriptomics will be reported as gene expression (mRNA levels) | Day 11 |
| Monocyte Transcriptomics | Monocyte transcriptomics will be reported as gene expression (mRNA levels) | Day 14 |
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052878 | Urolithiasis |
| D014545 | Urinary Calculi |
| D052801 | Male Urogenital Diseases |
| D002137 | Calculi |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |